Finding a treatment that works for you is important

From prophylaxis in adults and children (0-16 years), to helping to stop bleeds in adults and children on demand, you need a hemophilia A treatment that works for you. Click on the table below to learn more about the efficacy of Kogenate® FS Antihemophilic Factor (Recombinant).

15.2x Fewer Bleeds with Prophylaxis1

In a clinical study measuring the results of Kogenate® FS as on-demand treatment versus prophylaxis (regular use) in previously treated adults, routine prophylactic treatment was proven to reduce the frequency of bleeds regardless of age, presence or absence of target joints, and bleeding history.1

Average number of total bleeds per person per year1,2(P<0.0001)

37 2

On-demand (n=42)

Prophylaxis (n=42)

With prophylaxis 94% Reduction in average number of bleeds per year

Adult prophylaxis study design1,2:

Median annual bleed rate (ABR)1,2(P<0.0001)

On-demand (n=42)

33

Bleeds per year

Range: 0-104.1

Prophylaxis (n=42)

0

Bleeds per year*

Range: 0-19.8

Median=The middle value of a set of numbers placed in numerical order

*52% of the people receiving prophylaxis (22 out of 42) had 0 bleeds per year.1

Selected safety information

Your treatment for controlling joint bleeds

Average number of joint bleeds per year1,2

On-demand (n=42)

29

Joint bleeds
per year

Prophylaxis (n=42)

2

Joint bleeds
per year



Median number of joint bleeds per year1,3

On-demand (n=42)

24

Joint bleeds
per year

Range: 0-80.1

Prophylaxis (n=42)

0

Joint bleeds
per year*

Range: 0-18.4

Median=The middle value of a set of numbers placed in numerical order

*62% of the people receiving prophylaxis (26 out of 42) had 0 joint bleeds per year.3

Selected Safety Information

Eight times fewer bleeds

Children using Kogenate FS as a prophylaxis treatment saw eight times fewer joint bleeds per year compared with enhanced on-demand treatment.1,4

Over 8x fewer joint bleeds per patient per year1

The average rate of index joint bleeds for subjects on on-demand therapy was 4.89 bleeds per year, versus 0.63 bleeds per year in the prophylaxis group.

Study description:
A total of 65 boys <30 months of age with severe hemophilia A (FVIII level ≤2 IU/dL) with ≤2 bleeds into each index joint and normal baseline joint imaging were observed for up to 5.5 years in a multicenter, open-label, prospective, randomized, controlled clinical study.

Patients received Kogenate FS either 25 IU/kg every other day (primary prophylaxis, n=32) or at least 3 doses totaling a minimum of 80 IU/kg at the time of a bleeding episode (enhanced episodic, n=33).

Joint damage was evaluated by MRI or radiography, and the frequency of bleeding episodes was assessed.

Safety in routine prophylaxis

A life-threatening bleed is a major hemorrhage or loss of blood, such as an intracranial or gastrointestinal bleed, which may result in death.

Selected Safety Information

Proven results

Joint health is important for children living with hemophilia A. In one clinical study, 93% (25 of 27) of children with no pre-existing joint damage who were treated with Kogenate® or Kogenate® FS for routine prophylaxis up to 5.5 years had no joint damage as measured by magnetic resonance imaging (MRI), compared with 55% (16 of 29) of children given on-demand treatment with Kogenate or Kogenate FS.1,4

The difference between the 2 groups was statistically significant when using MRI but not when using x-ray alone.1

9 out of 10
children on routine prophylaxis experienced no joint damage, as measured by MRI.4

Joint Outcome Study (JOS) study description: A total of 65 boys aged 0 to 2.5 years at the beginning of the study, with severe hemophilia A (FVIII level ≤2 IU/dL) and with ≤2 bleeds into each index joint and normal baseline joint imaging were observed for up to 5.5 years in a multicenter, open-label, prospective, randomized, controlled clinical study. Patients received either 25 IU/kg every other day (routine prophylaxis; 32 people) or at least 3 doses totaling a minimum of 80 IU/kg at the time of a bleeding episode (enhanced episodic; 33 people). Joint damage was evaluated by MRI or radiography, and the frequency of bleeding episodes was assessed.1,4

Selected Safety Information

Safety in routine prophylaxis

A life-threatening bleed is a major hemorrhage or loss of blood, such as an intracranial or gastrointestinal bleed, which may result in death.

Inhibitor rates

Your body can make antibodies, called “inhibitors,” against factor VIII products including Kogenate FS, which may stop factor VIII from working properly. The inhibitor rates for Kogenate FS have been measured in several studies.

See the inhibitor rates reported for Kogenate FS

Your Bayer Rep is here to help

Get support.
Be connected.

Factor Matters is a support program designed to connect you to people, resources, and personalized information related to hemophilia A.

Sign up now